- Trial phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a regulatory filing would likely come no earlier than 2028-2029, with potential approval in the 2029-2030 timeframe. The drug is still investigational with no FDA submission filed.
- Why 4/10
- No hard dated binary catalyst is scheduled within the next ~12 months. The Phase 3 AMAZE trials began recruiting in August-September 2026 with estimated primary completion in 2028, so topline readouts are more than a year away. Zenagamtide is one of several pipeline assets at Novo Nordisk, a mega-cap company with many programs (CagriSema is more advanced, already filed for FDA approval).
Watch for Phase 3 AMAZE trial enrollment updates and any interim analysis announcements from Novo Nordisk, though no topline readouts are expected before 2028. The more immediate pipeline catalyst for NVO is the FDA decision on CagriSema, which has already been filed. Zenagamtide remains a longer-term pipeline story with promising early data but no near-term binary event.
Price Chart
Executive Summary
Zenagamtide (formerly amycretin, development code NN 9487) is Novo Nordisk's investigational unimolecular GLP-1/amylin receptor agonist for obesity and type 2 diabetes, being developed in both once-daily oral and once-weekly injectable formats. Phase 2 data showed up to 14.6% weight loss in type 2 diabetes and up to 24.3% in early obesity studies. The Phase 3 AMAZE program launched in mid-2026 and is actively recruiting, with estimated completion in 2028. The drug is not FDA approved and has no PDUFA date. For a mega-cap company like Novo Nordisk (NVO, ~$180B market cap) with multiple pipeline candidates, zenagamtide is a mid-to-long-term story with no near-term binary catalyst.
How It Works
Zenagamtide is a single engineered peptide molecule that simultaneously activates two appetite-regulating pathways: GLP-1 receptors (the same target as Ozempic/Wegovy) and amylin receptors (a satiety hormone pathway). It is designed to be taken either as a once-daily oral pill or a once-weekly subcutaneous injection for weight loss and type 2 diabetes.
Trial Status
Phase 2 data for type 2 diabetes was presented at ADA 2026 (June 2026) and published in The Lancet (August 2026), showing up to 14.6% mean weight loss and up to 1.71 percentage-point A1C reduction at 36 weeks. A Phase 1b/2a obesity study showed up to 24.3% mean weight loss at 36 weeks for the subcutaneous formulation. The Phase 3 AMAZE program launched in mid-2026: AMAZE 7 (injectable vs semaglutide, 650 patients, started Sep 2026) and AMAZE 9 (oral tablets vs placebo, 950 patients, started Aug 2026) are both recruiting. Additional AMAZE sub-studies cover sleep apnea and knee osteoarthritis. Primary completion dates for the Phase 3 trials are estimated in 2028.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 AMAZE topline readouts (estimated 2028, no firm date set)
- Potential interim analyses from Phase 3 trials (if any are scheduled, not yet disclosed)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report